Study: Artisanal CBD-Rich Extracts Show Long-Term Efficacy in Children with Epilepsy
Israeli researchers evaluated the efficacy and safety of artisanal CBD-rich extracts in a group of young people with types of epilepsy that are resistant to therapy. 51 percent of patients who received extracts for at least a year saw a significant decrease in the frequency of their seizures. Patients only had minor negative effects from CBD therapy.
“Artisanal cannabidiol-enriched cannabis may be an effective and safe long-term treatment for refractory epilepsy,” the authors wrote in their conclusion.
In 2018, the US Food and Drug Administration approved the sale of Epidiolex, a prescription drug used to treat Lennox-Gastaut syndrome and Dravet syndrome, two uncommon forms of severe epilepsy. Epidiolex contains a standardized formulation of cannabidiol produced from plants. The US Drug Enforcement Administration promptly downgraded Epidiolex to Schedule V of the US Controlled Substances Act, the category with the fewest restrictions permitted by federal law.
Full text of the study, “The long-term effectiveness and safety of cannabidiol-enriched oil in children with drug-resistant epilepsy,” appears in Pediatric Neurology. Additional information on cannabis and epilepsy is available from NORML.
Latest News
Cannabis Extraction Market: An In-depth Analysis from 2018-2027
Douglas, Isle Of Man - Cannabis extraction and extract have gone through exponential growth in the past decade. After being criminalized for a long time, the world saw and moved towards legalizing cannabis in many ...
Bright Green Issues Statement of Intent on Illegal Short Selling Activities
GRANTS, N.M. - Bright Green Corporation (NASDAQ: BGXX) (“Bright Green” or “the Company”), one of the very few companies selected by the U.S. government to grow, manufacture, and sell, legally under federal and state laws, ...
Global Cannabis Testing Market Analysis Report 2023-2030
DUBLIN - Global Cannabis Testing Market to Reach $2.8 Billion by 2030 In the changed post COVID-19 business landscape, the global market for Cannabis Testing estimated at US$1.1 Billion in the year 2022, is projected to reach ...